Add to ORKGLeucine rich repeat kinase 2 (LRRK2) mutations are a common cause of Parkinson’s disease (PD). Here, we identify inhibitors of LRRK2 kinase, which are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of PD. Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research
This journal suppl. contatin Abstracts of WFN XIX World Congress on Parkinson's Disease and Related ...
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease with a similar clinical ...
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although PD has lon...
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we id...
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, i...
Abstract Mutations in leucine-rich repeat kinase 2 (LRRK2) are one of the most common causes of fami...
Mutations in LRRK2 (leucine-rich repeat kinase 2) have been linked to inherited forms of PD (Parkins...
Mutations in Leucine-rich repeat kinase 2 (LRRK2) are a risk factor for and a cause of sporadic and ...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal ...
Abstract Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial P...
Mutations and variations in the leucine-rich repeat kinase 2 (LRRK2) gene are strongly associated wi...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Pa...
: Leucine-rich repeat kinase 2 (LRRK2) is a complex GTPase/kinase orchestrating cytoskeletal dynamic...
This is the final published version. Available from Oxford University Press via the DOI in this reco...
Current therapeutic approaches for Parkinson's disease (PD) are based around treatments that allevia...
This journal suppl. contatin Abstracts of WFN XIX World Congress on Parkinson's Disease and Related ...
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease with a similar clinical ...
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although PD has lon...
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we id...
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, i...
Abstract Mutations in leucine-rich repeat kinase 2 (LRRK2) are one of the most common causes of fami...
Mutations in LRRK2 (leucine-rich repeat kinase 2) have been linked to inherited forms of PD (Parkins...
Mutations in Leucine-rich repeat kinase 2 (LRRK2) are a risk factor for and a cause of sporadic and ...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal ...
Abstract Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial P...
Mutations and variations in the leucine-rich repeat kinase 2 (LRRK2) gene are strongly associated wi...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent known cause of late-onset Pa...
: Leucine-rich repeat kinase 2 (LRRK2) is a complex GTPase/kinase orchestrating cytoskeletal dynamic...
This is the final published version. Available from Oxford University Press via the DOI in this reco...
Current therapeutic approaches for Parkinson's disease (PD) are based around treatments that allevia...
This journal suppl. contatin Abstracts of WFN XIX World Congress on Parkinson's Disease and Related ...
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease with a similar clinical ...
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although PD has lon...